Profile

David D. Hurd, M.D.Wake Forest Baptist Health

Doctor Rating

4.7 out of 5

155 Ratings
14 Comments
 

David D. Hurd, M.D.

Professor,

Clinical Interests

Blood and Marrow Transplant, Bone Marrow and Stem Cell Transplantation, Clinical Trials, Hematologic Malignancies, Hematopoietic Stem Cell Transplantation, Hodgkin and Non-Hodgkin Lymphomas, Hodgkin's Disease, Lymphomas, Multiple Myeloma, Non-Hodgkin's Lymphoma

Contact Information

New Patient Appointments: 336-716-WAKE
Returning Patient Appointments: 336-713-5440
Department: 336-716-4464

Insurance Accepted »

Education & Training

  • B.S., University of Wisconsin-Madison, 1969
  • M.D., University of Illinois College of Medicine, 1974
  • Internship, Internal Medicine, University of Minnesota, 1975
  • Residency, Internal Medicine, University of Minnesota, 1977
  • Fellowship, University of Minnesota, 1979

Memberships

  • AAAS
  • Am Assn Of Cancer Research
  • Am Coll Of Physicians
  • Am Soc of Clinical Oncology
  • Am Soc of Hematology

NPI Number

  • 1962481879
David D. Hurd, M.D.

Doctor Rating

4.7 out of 5

155 Ratings
14 Comments
 

David D. Hurd, M.D.

Professor, Hematology & Oncology
Comprehensive Cancer Center

Research Interests

cancer/oncogenesis, cell growth, differentiation,d, drugs/therapeutic agents pharm, health services, research/outc, radiology imaging/nuclear medi

Contact Information

Academic: 336-716-2088 | Department: 336-716-4464

Recent Publications

Lamar ZS, Fino N, Palmer J, Gruber L, Morris BB, Raetskaya-Solntseva O, Kennedy L, Vaidya R, Hurd D, Zamkoff K. Dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin (EPOCH) with or without rituximab as first-line therapy for aggressive non-Hodgkin lymphoma. Clin Lymphoma Myeloma Leuk. 2016;16(2):76-81.

Lamar ZS, Fino N, Hurd D, Howard D, McIver ZA, Phillips GL, Vaidya R. Timing of salvage therapy and autologous hematopoietic cell transplant in relapsed hodgkin and non hodgkin lymphoma [abstract]. Biol Blood Marrow Transplant. 2016;22(3 Suppl 1):S127-S128.

Kennedy L, Filipek R, Russell G, Hurd D. Comparison of outcomes of two preparative regimens for lymphoma patients who are receiving autologous hematopoietic stem cell transplantations [abstract]. Biol Blood Marrow Transplant. 2015;21(2 Suppl 1):S122.

Greven KM, Case LD, Nycum LR, Zekan PJ, Hurd DD, Balcueva EP, Mills GM, Zon R, Flynn PJ, Biggs D, Shaw EG, Lesser G, Naughton MJ. Effect of ArginMax on sexual functioning and quality of life among female cancer survivors: results of the WFU CCOP Research Base Protocol 97106. J Community Support Oncol. 2015;13(3):87-94.

Holstein SA, Owzar K, Richardson PG, Jiang C, Hofmeister CC, Hassoun H, Hurd DD, Stadtmauer EA, Giralt S, Devine SM, Hars V, Postiglione JR, Weisdorf DJ, Vij R, Moreb JS, Callander NS, Martin TG, Shea TC, Anderson KC, McCarthy PL. Updated analysis of CALGB/ECOG/BMT CTN 100104: Lenalidomide (Len) vs. placebo (PBO) maintenance therapy after single autologous stem cell transplant (ASCT) for multiple myeloma (MM) [abstract]. J Clin Oncol. 2015;33(15 Suppl):8523.

Lamar ZS, Fitzgerald N, Palmer JM, Gruber L, RaetskayaSolntseva O, Kennedy L, Vaidya R, Zamkoff KW, Hurd DD. Single institution retrospective study of infusional etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin, (EPOCH) plus /- rituximab (R) as first line therapy for aggressive non-Hodgkin lymphoma [abstract]. J Clin Oncol. 2015;33(15 Suppl):e19514.

Lamar Z, Kennedy L, Kennedy B, Lynch M, Goad A, Hurd D, McIver Z. Ibrutinib and rituximab induced rapid response in refractory Richter syndrome. Clin Case Rep. 2015;3(7):615-617.

Pardee TS, Stadelman K, Isom S, Ellis LR, Berenzon D, Hurd DD, Howard DS, Harrelson R, Manuel M, Dralle S, Lyerly S, Powell BL. Activity of the mitochondrial metabolism inhibitor cpi-613 in combination with high dose Ara-C (HDAC) and mitoxantrone in high risk relapsed or refractory acute myeloid leukemia (AML) [abstract]. J Clin Oncol. 2015;33(15 Suppl):7015.

Pardee T, Pladna K, Isom S, Ellis LR, Berenzon D, Howard D, Manuel M, Dralle S, Hurd DD, Lyerly S, Powell BL. The mitochondrial metabolism inhibitor Cpi-613 in combination with high dose Ara-C (HDAC) and mitoxantrone is highly active in poor risk relapsed or refractory acute myeloid leukemia (AML) [abstract]. Blood. 2015;126(23):2556.

Kaplan LD, Jung SH, Stock W, Bartlett NL, Pitcher B, Byrd JC, Blum KA, LaCasce AS, Fulton N, Hsi ED, Hurd DD, Czuczman M, Leonard JP, Cheson BD. Bortezomib maintenance (BM) versus consolidation (BC) following aggressive immunochemotherapy and autologous stem cell transplant (ASCT) for untreated mantle cell lymphoma (MCL): CALGB (alliance) 50403 [abstract]. Blood. 2015;126(23):337.

Wang W, Bergman S, Hurd D, Zamkoff K, Beaty M. Large granular lymphocytic leukemia after allogeneic hematopoietic stem cell transplant [abstract]. Lab Invest. 2014;94(Suppl 1):384A.

Duckworth KE, Forti AM, Russell GB, Naik S, Hurd DD, McQuellon RP. Hematopoietic stem cell transplant candidate and designated proxy distress levels prior to hematopoietic stem cell transplantation. Am J Hosp Palliat Care. 2014;31(8):853-856.

Duckworth KE, Forti AM, Russell GB, Naik S, Hurd D, McQuellon RP. The process of advance care planning in HCT candidates and proxies: self-efficacy, locus of control, and anxiety levels. Am J Hosp Palliat Care. 2014;31(7):710-716.

Pardee TS, Lee K, Luddy J, Maturo C, Rodriguez R, Isom S, Miller LD, Stadelman KM, Levitan D, Hurd D, Ellis LR, Harrelson R, Manuel M, Dralle S, Lyerly S, Powell BL. A phase I study of the first-in-class antimitochondrial metabolism agent, CPI-613, in patients with advanced hematologic malignancies. Clin Cancer Res. 2014;20(20):5255-5264.

Wang X, Owzar K, Gupta P, Larson RA, Mulkey F, Miller AA, Lewis LD, Hurd D, Vij R, Ratain MJ, Murry DJ. Vatalanib population pharmacokinetics in patients with myelodysplastic syndrome: CALGB 10105 (Alliance). Br J Clin Pharmacol. 2014;78(5):1005-1013.

Pardee TS, Stadelman K, Isom S, Ellis LR, Berenzon D, Hurd DD, Harrelson R, Manuel M, Dralle S, Lyerly S [sic] [Lyerly ES], Powell BL. The mitochondrial metabolism inhibitor Cpi-613 is highly active in combination with high dose Ara-C (HiDAC) and mitoxantrone in a phase I study for relapsed or refractory acute myeloid leukemia (AML). Blood. 2014;124(21):3744.

Duckworth K, Forti A, Russell G, Campbell C, Naik S, Hurd D, McQuellon R. Advance care planning information and distress in hematopoietic cell transplant candidates and proxies [abstract]. Psychooncology. 2013;22(Suppl 2):100-101.

Gupta P, Mulkey F, Hasserjian RP, Sanford BL, Vij R, Hurd DD, Odenike OM, Bloomfield CD, Owzar K, Stone RM, Larson RA. A phase II study of the oral VEGF receptor tyrosine kinase inhibitor vatalanib (PTK787/ZK222584) in myelodysplastic syndrome: Cancer and Leukemia Group B study 10105 (Alliance). Invest New Drugs. 2013;31(5):1311-1320.

Naik S, D'Agostino R Jr, Lamar Z, Graham RM, Vatca M, Agnew E, Higgins A, Levitan D, Hurd D. Outcomes of second transplants for disease recurrence or for myelodysplasia (MDS) developing after an initial transplant (Tx) [abstract]. Biol Blood Marrow Transplant. 2012;18(2 Suppl 2):S340-S341.

McQuellon R, Duckworth K, Campbell C, Russell G, Naik S, Levitan D, Zamkoff K, McQuellon BT, Hurd D. Fear of recurrence following hematopoetic stem cell transplantation [abstract]. Psychooncology. 2012;21(Suppl 1):127.

Wendtner C-M, Hillmen P, Mahadevan D, Buhler A, Uharek L, Coutre S, Frankfurt O, Bloor A, Bosch F, Furman RR, Kimby E, Gribben JG, Gobbi M, Dreisbach L, Hurd DD, Sekeres MA, Ferrajoli A, Shah S, Zhang J, Moutouh-de Parseval L, Hallek M, et al. Final results of a multicenter phase 1 study of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia. Leuk Lymphoma. 2012;53(3):417-423.

McCarthy PL, Owzar K, Hofmeister CC, Hurd DD, Hassoun H, Richardson PG, Giralt S, Stadtmauer EA, Weisdorf DJ, Vij R, Moreb JS, Callander NS, Van Besien K, Gentile T, Isola L, Maziarz RT, Gabriel DA, Bashey A,. Lenalidomide after stem-cell transplantation for multiple myeloma. N Engl J Med. 2012;366(19):1770-1781.

Wilson WH, Jung SH, Porcu P, Hurd D, Johnson J, Martin SE, Czuczman M, Lai R, Said J, Chadburn A, Jones D, Dunleavy K, Canellos G, Zelenetz AD, Cheson BD, Hsi ED. A Cancer and Leukemia Group B multi-center study of DA-EPOCH-rituximab in untreated diffuse large B-cell lymphoma with analysis of outcome by molecular subtype. Haematologica. 2012;97(5):758-765.

High KP, Case D, Hurd D, Powell B, Lesser G, Falsey AR, Siegel R, Metzner-Sadurski J, Krauss JC, Chinnasami B, Sanders G, Rousey S, Shaw EG. A randomized, controlled trial of Panax quinquefolius extract (CVT-E002) to reduce respiratory infection in patients with chronic lymphocytic leukemia. J Support Oncol. 2012;10(5):195-201.

Fehniger TA, Larson S, Trinkaus K, Siegel MJ, Hurd DD, Blum KA, Goy A, Fenske TS, Cashen A, Wagner-Johnston ND, Carson KR, Bartlett NL. A phase 2 multicenter study of continuous dose lenalidomide in relapsed or refractory classical Hodgkin lymphoma [abstract]. Blood. 2012;120(21):Abstr 1623.

Loth K, Naik S, Kennedy LA, Levitan D, Zamkoff K, Hurd D. Infectious complications associated with the use of antithymocyte globulin in reduced intensity allogeneic transplants [abstract]. Biol Blood Marrow Transplant. 2011;17(2 Suppl 2):S355-S356.

Naik S, Shope D, Albright C, Graham R, Levitan D, Zamkoff K, D'Agostino R Jr, Hurd D. Transplant outcomes in multiple myeloma patients younger versus older than 60 years of age in the era of newer targeted agents [abstract]. Biol Blood Marrow Transplant. 2011;17(2 Suppl 2):S252-S253.

Stone RM, Moser B, Sanford B, Schulman P, Kolitz JE, Allen S, Stock W, Galinsky I, Vij R, Hurd D, et al. High dose cytarabine plus gemtuzumab ozogamicin for patients with relapsed or refractory acute myeloid leukemia: Cancer and Leukemia Group B study 19902. Leuk Res. 2011;35(3):329-333.

Bashey A, Owzar K, Johnson JL, Edwards PS, Kelly M, Baxter-Lowe L-A, Devine S, Farag S, Hurd D, Ball E, et al. Reduced-intensity conditioning allogeneic hematopoietic cell transplantation for patients with hematologic malignancies who relapse following autologous transplantation:. Biol Blood Marrow Transplant. 2011;17(4):558-565.

Furman RR, Grossbard ML, Johnson JL, Pecora AL, Cassileth PA, Jung S-H, Peterson BA, Nadler LM, Freedman A, Hurd DD, et al. A phase III study of anti-B4-blocked ricin as adjuvant therapy post-autologous bone marrow transplant: CALGB 9254. Leuk Lymphoma. 2011;52(4):587-596.

Giralt SA, Mangan KF, Maziarz RT, Bubalo JS, Beveridge R, Hurd DD, Mendoza FL, Rubenstein EB, DeGroot TJ, Schuster MW. Three palonosetron regimens to prevent CINV in myeloma patients receiving multiple-day high-dose melphalan and hematopoietic stem cell transplantation. Ann Oncol. 2011;22(4):939-946.

Pomper GJ, Wilson E, Isom S, Hurd DD. A validation study of new cryopreservation bags for implementation in a blood and marrow transplant laboratory. Transfusion. 2011;51(6):1291-1295.

Campbell C, McQuellon R, Duckworth K, Russell G, Hurd D, Levitan D, Naik S, Zamkoff K, McQuellon B, Sommer J. Health related quality of life, depressive symptoms and distress before and after hematopoietic cell transplantation [abstract]. Psychooncology. 2011;20(Suppl 1):81.

Fehniger TA, Larson S, Trinkaus K, Siegel MJ, Cashen AF, Blum KA, Fenske TS, Hurd DD, Goy A, Schneider SE, et al. A phase 2 multicenter study of lenalidomide in relapsed or refractory classical Hodgkin lymphoma. Blood. 2011;118(19):5119-5125.

Pardee T, DeFord-Watts LM, Peronto E, Levitan DA, Hurd DD, Kridel S. Altered lipid and mitochondrial metabolism are viable targets in acute leukemia [abstract]. Blood. 2011;118(21):1546.

Voorhees PM, Gasparetto C, Osman K, Richards KL, Ferraro M, Garcia R, MacLean J, Winans D, Moore D, Strader J, Orlowski RZ, Hurd DD. Vorinostat in combination with pegylated liposomal doxorubicin (PLD) and bortezomib (B) in patients with relapsed/refractory multiple myeloma (R/R MM): final results of a phase I study [abstract]. Blood. 2011;118(21):1705-1706.

Keung YK, Levitan D, Zamkoff K, Hurd D. Should the concern of myelodysplastic syndrome affect the decision of auto-SCT in lymphoma? [letter]. Bone Marrow Transplant. 2010;45(2):407-408.

Marks LB, Cirrincione C, Fitzgerald TJ, Laurie F, Glicksman AS, Vredenburgh J, Prosnitz LR, Shpall EJ, Crump M, Hurd DD, et al. Impact of high-dose chemotherapy on the ability to deliver subsequent local-regional radiotherapy for breast cancer: analysis of Cancer and Leukemia Group B Protocol 9082. Int J Radiat Oncol Biol Phys. 2010;76(5):1305-1313.

Keung YK, Beaty MW, Pettenati M, Levitan D, Hurd DD. Possible role of engraftment syndrome and autologous graft-versus-host disease in myelodysplastic syndrome after autologous stem cell transplantations: retrospective analysis and review of the literature. Clin Lymphoma Myeloma Leuk. 2010;10(2):129-133.

McQuellon R, Campbell C, Russell G, Duckworth K, Sommer J, McQuellon B, Hurd D. Quality of survivorship, surveillance behavior and treatment satisfaction following hematopoietic cell transplantation [abstract]. Psychooncology. 2010;19(Suppl 1):S98-S99.

Ritter EM, Zamkoff KW, Levitan DA, Hurd DD. The importance of timing of hematopoietic stem cell transplantation (HSCT) in patients with T-cell lymphomas (T-NHL) [abstract]. Biol Blood Marrow Transplant. 2010;16(2 Suppl 2):S238.

McCarthy PL, Owzar K, Anderson KC, Hofmeister CC, Hassoun H, Hurd DD, Stadtmauer EA, Giralt S, Hars V, Linker CA. Phase III intergroup study of lenalidomide versus placebo maintenance therapy following single autologous stem cell transplant (ASCT) for multiple myeloma (MM): CALGB 100104 [abstract]. J Clin Oncol. 2010;28(15 Suppl Pt 1):577s.

McCarthy PL, Owzar K, Anderson KC, Hofmeister CC, Hurd DD, Hassoun H, Giralt S, Stadtmauer EA, Richardson PG, Levitan D, et al. Phase III intergroup study of lenalidomide versus placebo maintenance therapy following single autologous hematopoietic stem cell transplantation (AHSCT) for multiple myeloma CALGB 100104 [abstract]. Blood. 2010;116(21):21-22.

Wendtner C, Hillmen P, Mahadevan D, Stilgenbauer S, Uharek L, Coutre S, Frankfurt O, Bloor A, Bosch F, Hurd DD, et al. Final results of the Phase I study of lenalidomide in patients with relapsed/refractory chronic lymphocytic leukemia (CLL-001 Study) [abstract]. Blood. 2010;116(21):591-592.

Voorhees PM, Gasparetto C, Osman K, Richards K, Ferraro M, Garcia R, MacLean J, Winans D, Moore D, Hurd DD, et al. Results of a phase I study of vorinostat in combination with pegylated liposomal doxorubicin and bortezomib in patients with relapsed/refractory multiple myeloma [abstract]. Blood. 2010;116(21):815.

Danhauer SC, Vishnevsky T, Campbell CR, McCoy TP, Tooze JA, Kanipe KN, Arrington SA, Holland EK, Lynch MB, Hurd DD, Cruz J. Music for patients with hematological malignancies undergoing bone marrow biopsy: a randomized controlled study of anxiety, perceived pain, and patient satisfaction. J Soc Integr Oncol. 2010;8(4):140-147.

Beaty MW, Pettenati M, Hurd DH [sic] [Hurd DD], Keung Y. Possible role of engraftment syndrome in myelodysplastic syndrome after autologous transplants [abstract]. Mod Pathol. 2009;22(Suppl 1):1161.

McClure White G, Campbell C, Russell G, Duckworth K, Hurd D, McQuellon R. Assessing distress and depression in hematopoietic stem cell transplant patients [abstract]. Psychooncology. 2009;18(Suppl 1):S43.

Wendtner CM, Mahadevan D, Coutre S, Hillmen P, Stilgenbauer S, Frankfurt O, Bloor A, Bosch F, Furman R, Hurd D, et al. A phase I dose-escalation of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia [abstract]. Haematologica. 2009;94(Suppl 2):371-372.

Storey JA, Connor RF, Lewis ZT, Hurd D, Pomper G, Keung YK, Lovato J, Torti SV, Torti FM, Molnar I, et al. The transplant iron score as a predictor of stem cell transplant survival. J Hematol Oncol. 2009;2():article 44.

All Publications

For a listing of recent publications, refer to PubMed, a service provided by the National Library of Medicine.

For a list of earlier publications, visit the Carpenter Library Publication Search.

Professor, Hematology & Oncology

Clinical Interests

Blood and Marrow Transplant, Bone Marrow and Stem Cell Transplantation, Clinical Trials, Hematologic Malignancies, Hematopoietic Stem Cell Transplantation, Hodgkin and Non-Hodgkin Lymphomas, Hodgkin's Disease, Lymphomas, Multiple Myeloma, Non-Hodgkin's Lymphoma
David D. Hurd, M.D.

David D. Hurd, M.D.

Professor, Hematology & Oncology
Comprehensive Cancer Center

Doctor Rating

4.7 out of 5

David D. Hurd, M.D.155 Ratings
14 Comments


 

Doctor Ratings

The overall Patient Rating score is the average of responses to the nine questions listed below. The questions are from the Press Ganey Patient Satisfaction Survey. Responses are measured on a 1 to 5 scale, where 1 represents "very poor" and 5 represents "very good."
Press Ganey Patient Satisfaction Survey

CP concern for questions/worries
4.8
CP efforts to include in decisions
4.8
CP explanations of prob/condition
4.8
CP spoke using clear language
4.8
Friendliness/courtesy of CP
4.9
Likelihood of recommending CP
4.8
Patients' confidence in CP
4.9
Time CP spent with patient
4.8
Wait time at clinic
4.0



Patient Comments

Comments are taken from the Care Provider section of the Press Ganey Patient Satisfaction Survey. Comments are posted exactly as they are written. Comments are added weekly. To protect patient privacy and confidentiality, patient names are not included.

12/23/2015

Happy with experience.

11/17/2015

*Dr. Hurd is an excellent doctor. He takes the time I need to answer my questions.

11/17/2015

I'm truly sorry that he is about to retire. He has been an excellent medical provider.

11/10/2015

Dr. Hurd is fabulous! I have only wonderful things to say about him. I hate that he is retiring for me but very happy for him. Not only is he an excellent Doctor, you also feel that he is a warm friend.

11/9/2015

As far as I'm concerned and from past experience WFU and their cancer team, including *Dr. Hurd and his PA's are the best. I'm always recommending Wake Forest.

10/28/2015

*Dr. Hurd and *Liz Holland, PA gets 10+++. Excellent providers.

9/29/2015

All good.

9/29/2015

Dr Hurd was always very friendly and carefully explained all facets of care and treatment.

9/16/2015

He is retiring and I wish him well!

8/25/2015

Dr. Hurd has ALWAYS been the most caring Dr. anyone could have. I will always remember him and have fond memories. He healed my wounds from a bad experience at Forsyth hospital.

8/25/2015

Questions submitting by emails always answered.

8/11/2015

SEEMED HE DIDN'T ADDRESS MY DISEASE AND HOW THE RESULTS OF THE SCAN AFFECTED ME. IT WAS OBVIOUS HE HADN'T REVIEWED MY CHART, NOR TAKEN T HE APPROPRIATE AMOUNT OF TIME TO DO SO IN THE EXAM ROOM. MY HISTORY AND ILLNESSES ARE EXTENSIVE AND RARE AND INVOLVED AND HE APPEARED TO NOT CARE OR REVIEW OR DISCUSS OR UNDERSTAND WHAT I WAS THERE FOR. VERY DISAPPOINTED. FIRST DOCTOR AT WAKE FOREST THAT I WAS UPSET WITH.

7/31/2015

I'm going to miss him retiring. *Hurd was a very caring physician.

7/6/2015

I recommend it to everyone I know that need care. I felt very welcomed and safe. I felt like I mattered.

Quick Reference

Request an Appointment
New Patients

336-716-WAKE
888-716-WAKE

Existing patients may contact the clinic directly.
Find a Doctor Ways to Give
USNWR 2015-2016Magnet Hospital RecognitionConsumer Choice2015 Best DoctorsJoint Commission Report

Disclaimer: The information on this website is for general informational purposes only and SHOULD NOT be relied upon as a substitute for sound professional medical advice, evaluation or care from your physician or other qualified health care provider.